Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies

Autor:	L. Rusen, Jeremy Rupon, Pablo Rendo, Kaan Kavakli, Joanne Fuiman, Joan M. Korth-Bradley, James Baumann, Christine Alvey, Francois Huard, Lynne Smith
Přispěvatelé:	Ege Üniversitesi
Rok vydání:	2018
Předmět:	Male previously untreated patients medicine.medical_specialty Haemophilia A Population 030204 cardiovascular system & hematology Hemophilia A 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Internal medicine medicine Moroctocog alfa Humans Prospective Studies 030212 general & internal medicine Child education Genetics (clinical) Paediatric patients education.field_of_study Factor VIII recombinant factor VIII business.industry Infant Newborn Infant clinical trial Hematology General Medicine medicine.disease Clinical trial Regimen previously treated patients Child Preschool Female Severe haemophilia A Safety business pharmacokinetics factor replacement
Zdroj:	Haemophilia. 24:604-610
ISSN:	1351-8216
DOI:	10.1111/hae.13466
Popis:	WOS: 000442583600048 PubMed ID: 29582525 IntroductionThe pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF-CC) have been demonstrated in haemophilia A patients aged 6years. AimThese studies aimed to further describe moroctocog alfa (AF-CC) experience in paediatric patients ( PfizerPfizer Pfizer
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d481121f47a0eff06ae5cc64c54cf64 https://doi.org/10.1111/hae.13466 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.